Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04998786

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse. (I2D IFM2021_03)

Sponsor: Nantes University Hospital

Conditions Multiple Myeloma at First Relapse

Interventions Dexamethasone Oral Iberdomide Ixazomib

Updated 7 times since 2021 Last updated: Apr 3, 2025 Started: Dec 14, 2021 Primary completion: Jan 1, 2030 Completion: Jan 1, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Myeloma at First Relapse and is currently ongoing. Nantes University Hospital leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

May 2025 — Present [monthly]

Active Not Recruiting PHASE2
Sep 2024 — May 2025 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jun 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2023 — Jun 2023 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Jan 2022 — Jan 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nantes University Hospital

Data source: Nantes University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Annecy, France , Bayonne, France , Bordeaux, France , Caen, France , Clermont-Ferrand, France , Dijon, France , La Roche-sur-Yon, France , Lille, France , Limoges, France , Lyon, France and 9 more locations